Aptose Biosciences (NASDAQ:APTO) Given Buy Rating at HC Wainwright

Aptose Biosciences (NASDAQ:APTO) (TSE:APS)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $2.00 target price on the biotechnology company’s stock.

Separately, StockNews.com began coverage on shares of Aptose Biosciences in a research report on Saturday, December 7th. They set a “hold” rating for the company.

Aptose Biosciences Trading Down 2.9 %

Shares of APTO stock opened at $0.18 on Tuesday. Aptose Biosciences has a twelve month low of $0.13 and a twelve month high of $2.71. The company has a market capitalization of $10.95 million, a PE ratio of -0.06 and a beta of 1.07. The firm has a fifty day simple moving average of $0.32 and a 200-day simple moving average of $0.51.

Institutional Trading of Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp increased its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent quarter. 26.62% of the stock is currently owned by institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.